Beset by a series of recalls of Tylenol and other popular over-the-counter drugs, Johnson & Johnson said Wednesday that it planned to revamp its quality controls, creating a single framework for its drug, medical device and consumer health care divisions. Ajit Shetty, the corporate vice president responsible for supply chain operations, will oversee the new system, reporting directly to William C. Weldon, Johnson & Johnson's chief executive. The company said it also planned to appoint chief quality officers for each of its three major divisions. Weldon first gave details of the plan in an interview Wednesday with The Wall Street Journal. The quality control reorganization comes after a number of recent recalls of Tylenol, Motrin and other products by McNeil Consumer Healthcare, a unit of Johnson & Johnson. The recalls have led to the temporary shutting of one manufacturing plant. McNeil's conduct surrounding the recalls is the subject of inquiry by both the House Committee on Oversight and Investigations and by the Food and Drug Administration's office of criminal investigations. In the last two years, FDA inspectors have found significant violations of manufacturing standards at two McNeil plants, according to the agency's website. In January, McNeil recalled millions of bottles of adult Tylenol, Motrin and other products made at a company plant in Puerto Rico after consumers complained about a moldy or musty odor in the products. The company said a byproduct of a chemical used to treat wooden transport pallets had leached into the products, causing the moldy smell. In April, McNeil recalled an estimated 136 million bottles of liquid children's Tylenol and other products made at a company plant in Fort Washington, Pa. The company recalled the products because they might have contained too much of the active drug ingredient or foreign particles, the FDA said. In July, McNeil said it was starting a program to improve manufacturing and quality and it has temporarily closed the Fort Washington plant. The recalls and plant shutdown cut Johnson & Johnson's sales by $200 million and its earnings by 5 cents a share in the second quarter, Dominic J. Caruso, the company's chief financial officer said during a recent conference call. He estimated that annual sales would decline by $600 million because of the plant closing. 